Everolimus-Based Therapy versus Chemotherapy among Patients with HR+/HER2− Metastatic Breast Cancer: Comparative Effectiveness from a Chart Review Study
Table 1
Comparison of patient baseline characteristics between everolimus-based therapy and chemotherapy.
Baseline characteristics1
Everolimus-based therapy
Chemotherapy
value†
Age (years)
Median (range)
64.0 (41.0, 89.0)
62.0 (38.0, 81.0)
Race/ethnicity, (%)
White
150 (64.1)
69 (50.4)
Non-white
84 (35.9)
68 (49.6)
Insurance plan type, (%)
Commercial/private insurance
133 (56.8)
80 (58.4)
0.466
Medicare only
81 (34.6)
50 (36.5)
Others
20 (8.5)
7 (5.1)
Index therapy line
First line
84 (35.9)
69 (50.4)
Second line
61 (26.1)
33 (24.1)
Third line and above
89 (38.0)
35 (25.5)
Adjusted CCI1
Median (range)
0.0 (0.0, 5.0)
0.0 (0.0, 8.0)
0.172
Sites of metastatic disease, (%)
Bone
150 (64.1)
77 (56.2)
0.132
Liver
82 (35.0)
71 (51.8)
Lung
92 (39.3)
84 (61.3)
<0.00
Visceral metastases
148 (63.2)
116 (84.7)
<0.00
Number of metastatic sites, (%)
1
111 (47.4)
24 (17.5)
<0.00
2
79 (33.8)
53 (38.7)
3
36 (15.4)
47 (34.3)
4
8 (3.4)
12 (8.8)
5
0 (0.0)
1 (0.7)
Physician assessed tumor volume
High
18 (7.7)
29 (21.2)
<0.00
Medium
132 (56.4)
92 (67.2)
Low
84 (35.9)
16 (11.7)
ECOG performance status
0—Asymptomatic
65 (27.8)
34 (24.8)
0.655
1—Symptomatic but completely ambulatory
100 (42.7)
68 (49.6)
2—Symptomatic, <50% in bed during the day
27 (11.5)
12 (8.8)
3—Symptomatic, >50% in bed, but not bedbound
4 (1.7)
1 (0.7)
Not recorded in medical record
38 (16.2)
22 (16.1)
Prior chemotherapy in mBC setting
52 (22.2)
23 (16.8)
0.209
Disease status
Recurrent patients with adjuvant ET, (%)
148 (63.2)
106 (77.4)
Recurrent patients without adjuvant ET, (%)
37 (15.8)
9 (6.6)
De novo, (%)
49 (20.9)
22 (16.1)
Months from initiation of last adjuvant endocrine therapy to the first stage IV mBC diagnosis
Median (range)
17.9 (0.0, 149.6)
14.2 (0.0, 163.7)
0.458
Statistical comparisons were conducted using Wilcoxon rank-sum tests for continuous variables and chi-square tests for categorical variables. . Notes: 1The adjusted CCI calculated the comorbidity index excluding metastatic breast cancer (score of 6).
